Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer
Nuclear transporter importin-β1 is emerging as an attractive target by virtue of its prevalence in many cancers. However, the lack of druggable inhibitors restricts its therapeutic proof of concept. In the present work, we optimized a natural importin-β1 inhibitor DD1 to afford an improved analog DD...
Main Authors: | Jia-Luo Huang, Xue-Long Yan, Dong Huang, Lu Gan, Huahua Gao, Run-Zhu Fan, Shen Li, Fang-Yu Yuan, Xinying Zhu, Gui-Hua Tang, Hong-Wu Chen, Junjian Wang, Sheng Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383523002794 |
Similar Items
-
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
by: Takashi Kawahara, et al.
Published: (2023-03-01) -
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01) -
Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01) -
Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
by: Evgeniya Sharova, et al.
Published: (2021-03-01) -
MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC
by: Yuanyuan Wang, et al.
Published: (2024-04-01)